

Elena Raschi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8774793/elena-raschi-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

3,422

citations

30

h-index

58

g-index

65

ext. papers

3,804

ext. citations

5.9

avg, IF

4.51

L-index

#	Paper	IF	Citations
62	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 265	5.7	5
61	New insight into antiphospholipid syndrome: antibodies to β 2-glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019 , 104, 819-826	6.6	21
60	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. <i>Open Rheumatology Journal</i> , 2018 , 12, 248-260	0.2	3
59	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. <i>Arthritis Research and Therapy</i> , 2018 , 20, 187	5.7	15
58	Mechanisms of Action of the Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 12, 31-46	0.3	0
57	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016 , 9, 389-400	2.8	24
56	OP0285 The Pathogenic Role of Immune Complexes Containing Scleroderma-Specific Autoantibodies in the Inductor Phase of the Disease. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 180.2-180.4	2.4	24
55	Update on the pathogenesis and treatment of the antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 476-82	5.3	29
54	A3.5 Toll like receptors: a crossroad in scleroderma etiopathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A43.2-A44	2.4	
53	Antiendothelial Cell Antibodies 2014 , 723-729		
52	β 2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. <i>Journal of Autoimmunity</i> , 2014 , 55, 42-50	15.5	42
51	Toll-like receptor 4 and β 2 glycoprotein I interaction on endothelial cells. <i>Lupus</i> , 2014 , 23, 1302-4	2.6	17
50	Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1347-56		71
49	Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. <i>Arthritis Research and Therapy</i> , 2013 , 15, R151	5.7	54
48	OP0060 Beta2GPI and TLR4 interaction on endothelial cells: A bridge between innate and adaptive immunity in APS. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 73.2-73	2.4	
47	Obstetric and vascular APS: same autoantibodies but different diseases?. <i>Lupus</i> , 2012 , 21, 708-10	2.6	34
46	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity? 2012 , 79-101		0

45	What are the Target Cells and Receptors that are Recognized by Antiphospholipid Antibodies? 2012 , 103-113		
44	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 330-9	8.1	374
43	Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1504-12		43
42	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. <i>Journal of Autoimmunity</i> , 2009 , 32, 60-3	15.5	21
41	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009 , 10, 55-67	0.3	3
40	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. <i>Lupus</i> , 2008 , 17, 937-42	2.6	51
39	Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 236-50	5.3	173
38	Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. <i>Transplantation</i> , 2008 , 86, 1445-51	1.8	22
37	Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. <i>Clinical Reviews in Allergy and Immunology</i> , 2008 , 34, 332-7	12.3	27
36	Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies. <i>Clinical Reviews in Allergy and Immunology</i> , 2007 , 32, 67-74	12.3	18
35	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1327-33	2.4	160
34	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES 2007 , 725-731		2
33	Role of anti-β glycoprotein I antibodies in antiphospholipid syndromeglycoprotein I antibodies in antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2007 , 32, 67-73	12.3	
32	Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block: lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , 2006 , 54, 356-9		23
31	Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1069, 364-76	6.5	19
30	Interaction of Antiphospholipid Antibodies with Endothelial Cells 2006 , 415-426		
29	Humoral autoimmunity against endothelium: theory or reality?. <i>Trends in Immunology</i> , 2005 , 26, 275-81	14.4	45
28	Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 462-7	2.4	76

27	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2004 , 3, 510-5	13.6	47
26	Endothelial cell activation by antiphospholipid antibodies. <i>Clinical Immunology</i> , 2004 , 112, 169-74	9	76
25	Inflammatory response and the endothelium. <i>Thrombosis Research</i> , 2004 , 114, 329-34	8.2	62
24	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. <i>Blood</i> , 2003 , 101, 3495-500	2.2	260
23	Endothelium as a target for antiphospholipid antibodies. <i>Immunobiology</i> , 2003 , 207, 29-36	3.4	34
22	Endothelium activation in the anti-phospholipid syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2003 , 57, 282-6	7.5	16
21	Endothelium and the brain in CNS lupus. <i>Lupus</i> , 2003 , 12, 919-28	2.6	90
20	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1602-13		118
19	Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1595-601		32
18	Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis. <i>Clinical and Experimental Immunology</i> , 2002 , 128, 187-94	6.2	19
17	Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. <i>Autoimmunity Reviews</i> , 2002 , 1, 55-60	13.6	18
16	Antiphospholipid/Endothelial Cell Interaction in the Pathogenesis of the Antiphospholipid Syndrome 2002 , 79-89		0
15	Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2870-8		227
14	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. <i>International Immunology</i> , 2001 , 13, 349-57	4.9	39
13	Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. <i>American Journal of Kidney Diseases</i> , 2001 , 37, 490-8	7.4	151
12	Antiphospholipid antibodies and the endothelium. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 587-602	2.4	44
11	Functional Heterogeneity of Pathogenic Anti-Endothelial Cell Antibodies 2001 , 211-220		1
10	Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. <i>Arthritis and Rheumatism</i> , 2000 , 43, 140-50		253

9	Anti-endothelial cell antibodies in patients with coronary atherosclerosis. <i>Immunology Letters</i> , 2000 , 73, 23-7	4.1	22
8	The story of the murine antiendothelial monoclonal antibody BGM. From patients bedside to laboratory bench and from animal models to patients. <i>Clinical Reviews in Allergy and Immunology</i> , 2000 , 18, 3-9	12.3	
7	Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. <i>Journal of Autoimmunity</i> , 2000 , 15, 237-40	15.5	126
6	Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. <i>Lupus</i> , 1999 , 8, 423-9	2.6	76
5	Antiendothelial Cell Antibodies (AECA): From a Laboratory Curiosity to Another Useful Autoantibody 1999 , 285-294		6
4	Beta2-glycoprotein I as a cofactor for anti-phospholipid reactivity with endothelial cells. <i>Lupus</i> , 1998 , 7 Suppl 2, S44-7	2.6	43
3	Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. <i>Journal of Immunology</i> , 1998 , 160, 5572-8	5.3	92
2	Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies. <i>American Journal of Reproductive Immunology</i> , 1997 , 38, 212-7	3.8	45
1	Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. <i>Clinical and Experimental Immunology</i> , 1997 , 110, 479-84	6.2	23